Plexxikon and MSD team up to evaluate PLX3397 in combination with KEYTRUDA
7 May 2015 | By Victoria White
Plexxikon and MSD have announced a collaborative clinical trial that will evaluate the combination of PLX3397 and KEYTRUDA in melanoma...
List view / Grid view
News
Pfizer announces key appointments in BioTherapeutics R&D and Rinat
7 May 2015 | By Victoria White
Pfizer has made two strategic appointments in the leadership of their BioTherapeutics Research and Development and Rinat units...
Positive preclinical data for Dicerna Pharmaceuticals’ DsiRNA-EX Conjugates presented at TIDES 2015
6 May 2015 | By Victoria White
Dicerna Pharmaceuticals has presented positive preclinical data on its proprietary DsiRNA-EX Conjugate-mediated delivery technology at TIDES 2015...
ROCK inhibitors could stop the spread of melanoma cells
6 May 2015 | By Victoria White
Scientists at The Institute of Cancer Research have found that ROCK inhibitors dramatically reduced the ability of melanoma cells to move through tissue...
Gilead acquires EpiTherapeutics for $65 million
6 May 2015 | By Victoria White
Gilead Sciences has acquired EpiTherapeutics, a scientific leader in the field of epigenetics with a library of first-in-class inhibitors, for $65 million.
MabVax Therapeutics’ HuMab 5B1 antibody successfully clears important early toxicology testing
6 May 2015 | By Victoria White
The final report on toxicology testing of HuMab 5B1 shows that it had no significant adverse findings even at the highest dosage levels tested...
ME-344 shows enhanced anti-tumour activity in combination with tyrosine-kinase inhibitor in preclinical studies
6 May 2015 | By Victoria White
MEI Pharma has announced new preclinical data showing mitochondria-specific effects of the Company's investigational drug candidate ME-344 in cancer cells...
Discovery could help reverse glucocorticoid resistance in young leukaemia patients
5 May 2015 | By
Researchers led by St. Jude Children’s Research Hospital scientists have identified a mechanism that helps leukaemia cells resist glucocorticoids...
Breast cancer vaccines may work better with silicon microparticles
5 May 2015 | By Victoria White
The effectiveness of cancer vaccines could be dramatically boosted by first loading the cancer antigens into silicon microparticles...
Drug discovery company Selvita establishes UK subsidiary in Cambridge
5 May 2015 | By Victoria White
Selvita, a global drug discovery company with offices in the US and Poland, is opening its first office in the UK in Cambridge...
Kallistem announces a world first: human spermatogenesis in vitro
5 May 2015 | By Victoria White
Kallistem has produced a fully formed human spermatozoa in the laboratory setting, using patient testicular biopsies containing only immature germ cells...
Shire and Foundation Fighting Blindness announce new adRP research agreement
5 May 2015 | By Victoria White
Shire and the Foundation Fighting Blindness have entered in to an agreement focused on furthering research for a novel treatment for adRP...
The Michael J. Fox Foundation and Prothena partner to accelerate discovery of novel biomarkers for Parkinson’s disease
5 May 2015 | By Victoria White
MJFF and Prothena have teamed up to accelerate the discovery of novel biomarkers and development of assays to measure Parkinson's disease progression...
ReNeuron gets approval to start a Phase I/II clinical trial in the US in retinitis pigmentosa
5 May 2015 | By Victoria White
ReNeuron has received approval from the FDA to commence a Phase I/II clinical trial in the US with its hRPC therapy candidate for retinitis pigmentosa...
Scientists identify key receptors behind development of acute myeloid leukaemia
30 April 2015 | By Victoria White
Researchers have found that ITIM - receptors are important to the development of acute myeloid leukaemia (AML), providing a target for potential therapies...
